CasNo.152459-95-5,imatinib,(152459-95-5) Suppliers

100 Gram	Negotiable

Min.Order :100 Gram
Purity: ≥98.5%
Payment Terms : L/C,D/P,T/T,Other

Keywords

imatinib 152459-95-5 C29H31N7O

Quick Details

Appearance:Off-white to brown powder
Application:Tyrosine kinase inhibitor. It is used for chronic myeloid leukemia (CML) in the progenitor cell critical phase, accelerated phase, and chronic phase when alpha interferon therapy is ineffective, as we
PackAge:25kg/bag/drum,according to customer's requirment
ProductionCapacity:100|Kilogram|Week
Storage:Storage in warehouse with well-ventilation, keep away from fire source, avoid moisture?&?sunshine.
Transportation:By air/by sea/ by express

Superiority:

Henan Wising Chem Co., Ltd is a national high-tech enterprise with a passion for selling and an emphasis on customer care.

We are committed to providing quality chemical products that help us become one of the most reputable, reliable and leading chemical products suppliers in the domestic and global markets.

We purpose to bring our value clients the best quality products, the most competitive prices, the shortest delivery and the best service.

Our customers include BASF, Bayer, Merck, AstraZeneca, Sun Pharma, Shanghai Pharmaceuticals, MSN Laboratories, Unither Pharmaceuticals, Cadila Healthcare, and Abbott, Amgen in the US.

Wising Chem is a reliable distributor in domestic and global markets, we own an excellent reserch team based on Zhengzhou University, Shanghai Medical College of Fudan University and Henan University of Animal Husbandry&Economy, we focus on Pharmaceutical intermediates, API, rare chemiclas, and fine chemicals.

Details:

Tyrosine kinase inhibitor. It is used for chronic myeloid leukemia (CML) in the progenitor cell critical phase, accelerated phase, and chronic phase when alpha interferon therapy is ineffective, as well as gastrointestinal interstitial tumors (GIST). Imatinib mesylate inhibited Bcr-Abl tyrosine kinase at the cellular level both in vitro and in vivo, and selectively inhibited proliferation and induced apoptosis in fresh cells of Bcr-Abl-positive cell lines, Ph chromosome-positive chronic granulocytic leukemia and acute lymphoblastic leukemia patients. In addition, imatinib mesylate inhibited platelet-derived growth factor (PDGF) receptor, stem cell factor (SCF), and c-Kit receptor tyrosine kinase, thereby inhibiting cellular behavior mediated by PDGF and stem cell factor.